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Varicella-zoster virus (VZV) causes chickenpox (var-
icella), becomes latent in cranial nerve and dorsal
root ganglia, and can reactivate many years later to
produce shingles (zoster) and postherpetic neuralgia
(PHN). Elderly and immunocompromised individ-
uals are also at risk for complications of VZV reacti-
vation involving the central nervous system (CNS),
including myelitis, large-vessel encephalitis/granulo-
matous arteritis, small-vessel encephalitis, menin-
goencephalitis, and ventriculitis. Peripheral nervous
system (PNS) complications range from zoster and
postherpetic neuralgia to postinfectious polyneuritis
(Guillain±Barre syndrome, GBS). These complica-
tions can occur with or without cutaneous manifest-
ations. An increase in elderly and immuno-
compromised individuals will likely result in a higher
prevalence of these conditions; therefore, VZV can
be seen as a ``re-emerging'' infection of the early
twenty-®rst century. In this review, we summarize
our experience and the existing literature on CNS
and PNS complications of VZV reactivation. Special
attention is paid to reports of complications without
rash, as these entities are more dif®cult to diagnose.
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V
aricella-zoster virus (VZV) is a human alphaher-
pesvirus that causes chickenpox (varicella), becomes
latent in cranial nerve and dorsal root ganglia, and
can reactivate many years later to produce shingles
(zoster) and postherpetic neuralgia (PHN). Elderly
and immunocompromised individuals are also at risk for
complications of VZV reactivation involving both the central
nervous system (CNS) and the peripheral nervous system
(PNS), and which can occur with or without skin lesions. As
the number of elderly population in our society increases, as
well as the number of immunocompromised patients due to
human immunode®ciency virus (HIV) infection/acquired im-
mune de®ciency syndrome (AIDS), and the use of immuno-
suppressive medications (e.g., post-transplant), or the
complications of drug therapy (e.g., antineoplastic agents) also
increases, a larger population becomes susceptible to the rarer,
and more serious complications of VZV reactivation. Therefore,
VZV can be seen as a ``re-emerging'' infection of the early
twenty-®rst century.
PRIMARY INFECTION: VARICELLA (CHICKENPOX)
Primary VZV infection produces varicella (chickenpox), a
typically mild contagious disease of childhood. By adult life,
nearly everyone in North America is seropositive.
Approximately 4 million cases occur annually in the U.S.A.,
with 90% of cases in individuals 1±14 y of age (Preblud, 1986).
In northern regions, only 2% of varicella occurs after age 20,
whereas in tropical climates a higher incidence of varicella is
seen in adults (Nassar and Touma, 1986; Long®eld et al, 1990).
In temperate climates, chickenpox peaks in the spring, with
another smaller peak in winter (Preblud and D'Angelo, 1979;
Preblud et al, 1984). It is thought that the disease is transmitted
by direct contact or by aerosols containing virus (Leclair et al,
1980; Gustafson et al, 1982; Josephson and Gombert, 1988).
Infection is probably initially in the respiratory tract, followed
by viral replication, most likely in the pharynx and regional
lymph nodes (Tomlinson, 1939; Fenner, 1948; Grose, 1981).
The incubation period in healthy children is 9±21 d (Fenner,
1948; Grose, 1981; Preblud et al, 1984). Viremia in immuno-
competent varicella patients has been demonstrated 1±11 d
before rash (Asano et al, 1985; Kallander et al, 1989),
predominantly in lymphocytes (Ozaki et al, 1986; Vonsover et
al, 1987; Koropchak et al, 1989). Immunologic evidence
indicates that subclinical reinfection with VZV is fairly common
(Baba et al, 1986; Wharton, 1996). Fever, myalgia, and
arthralgias precede or coincide with rash. The exanthem of
chickenpox consists of macules and papules that develop into
vesicles surrounded by an erythematous halo. Vesicles, which
re¯ect degenerative changes of the corium and dermis, develop
quickly and are characterized by multinucleated giant cells and
intranuclear Cowdry type A inclusions (Tyzzer, 1906), a
hallmark of herpesvirus family infection. Vesicles contain
abundant infectious virus that can be isolated in cell culture
(Weller et al, 1958). Rash usually begins on the trunk, then
spreads to the face, limbs, and often to the buccal and
pharyngeal mucosa. Skin areas that are sunburned or subject to
irritation (e.g., from diapers) often exhibit a denser rash. New
vesicles form within the ®rst 4 d after outbreak, while crusting
starts after 2±3 d; thus, both crusting and fresh vesicles may be
seen at the same time. Patients are considered infectious from 2
d before rash until all vesicles have crusted, typically 6 d after
the onset of rash. Immunization of children 12±18 mo old with
a live attenuated varicella vaccine (Oka strain) may eventually
shift the average age of infection to older susceptible individuals
(Halloran, 1996).
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REACTIVATION: ZOSTER (SHINGLES, GANGLIONITIS)
AND POSTHERPETIC NEURALGIA (PHN)
Herpes zoster is a common disorder, with estimates of 300 000±
850 000 cases occurring annually in the U.S.A. Except in
immunocompromised individuals (especially AIDS patients), zoster
is a disease of the elderly. The incidence among people over age 50
is double that of people under 50 (Harnisch, 1984), which
ultimately translates into an 8±10-fold increased frequency in
people over age 60 compared with those under 60. As the aging
population increases, the incidence of zoster-associated morbidity
and mortality is also expected to increase. Varicella in infancy may
predispose to zoster earlier in life (Guess et al, 1985). The incidence
of recurrent zoster is less than 5% (Hope-Simpson, 1965). Although
varicella outbreaks occur most often in the spring, zoster may
develop at any time of the year. The risk of zoster in vaccinated
individuals compared with those who developed naturally occur-
ring chickenpox will not be known for decades. Some investigators
have predicted an increased incidence of zoster with widespread use
of the live attenuated varicella vaccine (Garnett and Grenfell, 1992;
Wharton, 1996). Other evidence indicates that, in children with
leukemia who had been vaccinated, the incidence of zoster is less
than in leukemic children who had naturally occurring chickenpox
(Brunell et al, 1986; Hardy et al, 1991).
Herpes zoster is characterized by pain and a vesicular eruption on
an erythematous base in 1±3 dermatomes. All levels of the neuraxis
may be involved in zoster, with thoracic zoster being the most
common, followed by lesions on the face, most often in the
ophthalmic division of the trigeminal nerve. The latter is frequently
accompanied by zoster keratitis, a potential cause of blindness if not
recognized and treated promptly. Thus, if visual symptoms are
present in a patient with trigeminal distribution zoster, they should
have an immediate slitlamp examination by an ophthalmologist.
Maxillary and mandibular trigeminal distribution zoster with
osteonecrosis and spontaneous tooth exfoliation has also been
described in adults (Manz et al, 1986) and children (Garty et al,
1985). The seventh cranial nerve is also commonly involved.
Weakness of all facial muscles of one side develops in conjunction
with rash in the ear (zoster oticus) or on the ipsilateral anterior two-
thirds of the tongue or hard palate. Unless searched for in patients
with facial weakness, vesicles in either site are easily overlooked.
The combination of zoster oticus and peripheral facial weakness
constitutes the Ramsay Hunt syndrome, and the prognosis for
recovery from facial weakness or paralysis is not as favorable as in
idiopathic Bell's palsy. Zoster may be accompanied by ophthalmo-
plegia, most commonly affecting the third cranial nerve (Thomas
and Howard, 1972), optic neuritis (Miller et al, 1986), or both
(Carroll and Mastaglia, 1979), and less often lower cranial nerve
palsies (Crabtree, 1968; Steffen and Selby, 1972). Zoster-associated
cranial neuropathy often occurs weeks after acute VZV infection.
One explanation for late-onset zoster cranial neuropathy is that
virus spreads slowly along trigeminal and other ganglionic afferent
®bers to small vessels supplying cranial nerves.
Most neurologic complications of zoster manifest as postherpetic
neuralgia (PHN), de®ned as pain persisting more than 4±6 wk after
rash. Age is the most important factor in predicting the develop-
ment of PHN (Brown, 1976; Ragozzino et al, 1982). The risk of
PHN in zoster patients over age 50 ranges from 43% to 47.5%. The
incidence of PHN also appears to be slightly greater in women
(Hope-Simpson, 1975) and after trigeminal distribution zoster
(DeMoragas and Kierland, 1957; Rogers and Tindall, 1971; Hope-
Simpson, 1975).
The mechanism of PHN is unknown. The detection of VZV-
speci®c proteins in mononuclear cells (MNC) of patients with
PHN (Vafai et al, 1988b) suggested that persistence of VZV may
result in PHN. Later, VZV DNA was shown to persist in blood
MNC of PHN patients (Mahalingam et al, 1995) compared with
zoster patients without PHN. It is possible that MNC traf®cking
through such ganglia encounter and engulf virus whose DNA can
then be ampli®ed by polymerase chain reaction. Ganglia need to be
analyzed at autopsy from individuals who suffered from PHN at the
time of death. If a greater virus burden could be demonstrated in
these ganglia than has been found during latency (Mahalingam et al,
1993), this would provide a rationale for aggressive treatment of
PHN patients with antivirals. Meanwhile, the existence of
ganglionitis without rash is further supported by the presence of
radicular pain up to 100 d preceding zoster (Gilden et al, 1991), so-
called preherpetic neuralgia. Furthermore, a recent report described
four patients with acute trigeminal distribution zoster who, after
years free from pain, developed severe trigeminal ``PHN'' (Schott,
1998).
CNS AND PNS COMPLICATIONS OF VZV
REACTIVATION
In immunocompetent and especially in immunocompromised
patients, CNS complications can occur after VZV reactivation
when virus spreads to the spinal cord, brain, or arteries.
Immunocompetent individuals may develop myelitis or large-
vessel encephalitis/granulomatous arteritis, whereas immunocom-
promised patients develop small-vessel encephalitis, meningoence-
phalitis, or ventriculitis. Some patients develop both large- and
small-vessel disease, although one form usually predominates
(Gilden et al, 1996). In addition, PNS complications can occur,
including postinfectious polyneuritis (Guillain±Barre syndrome,
GBS). These clinical entities are reviewed in Gilden et al (2000).
COMPLICATIONS OF VZV REACTIVATION WITHOUT
RASH
Because of the relatively distinct features of skin ®ndings associated
with VZV primary infection and zoster, diagnosis is fairly
straightforward; however, many complications of VZV reactivation
can occur without rash, and these pose a more dif®cult diagnosis for
neurologists, dermatologists, and colleagues caring for the patient.
These include zoster sine herpete, encephalitis, myelitis, poly-
neuritis cranialis, and ``Bell's'' palsy, all caused by VZV without
rash, and are reviewed below. Table I lists the published cases of
VZV complications, without rash, seen at the University of
Colorado Health Sciences Center in the past decade.
The ®rst case of zoster sine herpete (shingles without rash) was
reported nearly 100 y ago. A 38-y-old man developed acute
thoracic-distribution pain and hyperesthesia, a dilated pupil, CSF
pleocytosis (predominantly mononuclear), and a negative serologic
test for syphilis (Widal, 1907). He was presumed to have zoster sine
herpete even though serologic tests for VZV were not done.
Similarly, two patients who experienced segmental pain, hyper-
esthesias, and focal weakness were presumed to have zoster sine
herpete despite lack of serologic con®rmation (Weber, 1916). The
notion of zoster sine herpete received further credence when Lewis
(1958) described numerous zoster patients who, days later, also
developed pain without rash in a different dermatome distribution,
often on the opposite side.
The ®rst serologic evidence of zoster sine herpete occurred in a
physician who developed acute trigeminal distribution pain asso-
ciated with a 4-fold rise in complement-®xing antibody to VZV,




VZV myelitis 4 Gilden et al, 1994a
Zoster sine herpete 2; 1 Gilden et al, 1994b;
Amlie-Lefond et al, 1996
VZV encephalitis 5 Amlie-Lefond et al, 1995
VZV meningoradiculitis 1 Dueland et al, 1991
VZV encephalomyelitis 1 Kleinschmidt-DeMasters et al, 1998
VZV ventriculitis 2 Kleinschmidt-DeMasters et al, 1996
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but not to HSV (Easton, 1970). Virologic con®rmation of zoster
sine herpete did not come until the analysis of two men with
thoracic-distribution radicular pain that had lasted for months to
years revealed ampli®able VZV DNA, but not HSV DNA, in their
CSF and blood MNC (Gilden et al, 1994b). After diagnosis, both
men were treated successfully with intravenous acyclovir. A third
virologically con®rmed case of thoracic-distribution zoster sine
herpete persisting for years included the demonstration of frequent
®brillation potentials restricted to chronically painful thoracic root
segments (Amlie-Lefond et al, 1996); however, the third patient did
not improve after treatment with intravenous acyclovir and oral
famciclovir.
VZV encephalitis without rash may occur, with the typical
clinical picture being an immunocompromised individual (usually
suffering from AIDS) who develops CNS disease at the time of
acute zoster, or who may have a history of zoster weeks to months
earlier, or even recurrent zoster. CNS disease in such patients
develops more often in the absence of acute zoster than at the time
of acute zoster (Amlie-Lefond et al, 1995). Encephalitis is usually of
the ``small vessel'' type (Gilden et al 2000), and disease is usually
protracted. Diagnosis may be dif®cult unless the clinician is alert to
the history of recurrent zoster followed by the typical clinical
features and multifocal lesions seen by brain MRI in ``small vessel''
encephalitis. Many patients die of chronic progressive VZV
encephalitis without ever having developed rash (Amlie-Lefond et
al, 1995; Gilden et al, 1996). The most extreme example of VZV
infection of the nervous system we encountered was a 77-y-old
man with T cell lymphoma who developed a fatal meningor-
adiculitis and died 3 wk after the onset of neurologic disease
(Dueland et al, 1991). He did not develop zoster before or during
neurologic disease. Postmortem examination revealed hemorrha-
gic, in¯ammatory lesions with Cowdry A inclusions in meninges
and nerve roots extending from cranial nerve roots to the cauda
equina. The brain contained similar lesions, although to a lesser
extent. We found VZV antigen and nucleic acid, but not HSV or
CMV antigen or nucleic acid, in infected tissue at all levels of the
neuraxis. Thus, VZV should be included in the differential
diagnosis of acute encephalomyeloradiculopathy, particularly since
antiviral treatment is available.
Acute VZV myelopathy may also occur in the absence of rash.
The initial description was of a 31-y-old immunocompetent man
who developed transverse myelitis with partial recovery (Heller et
al, 1990). Disease was attributed to VZV based on the development
of antibody in CSF. Later, Gilden et al (1994b) encountered two
patients with VZV myelopathy in the absence of rash. The ®rst
patient developed zoster followed by myelopathy 5 mo later, at
which time ampli®able VZV DNA was detected in CSF. A second
patient developed myelopathy at the time of acute zoster. The
myelopathy resolved, but recurred 6 mo later. Five months after the
recurrence of myelopathy, the patient's CSF contained both
ampli®able VZV DNA as well as antibody to VZV. Overall, the
spectrum of VZV myelopathy can be broad, ranging from acute to
chronic and rarely recurrent myelopathy.
Further VZV involvement of the CNS without rash was veri®ed
by the intrathecal synthesis of antibodies to VZV in two patients
with aseptic meningitis (Martinez-Martin et al, 1985), later in four
additional patients with aseptic meningitis (Echevarria et al, 1987),
and in one patient with acute meningoencephalitis (Vartdal et al,
1982). We encountered an adult man who was taking low-dose
methotrexate for rheumatoid arthritis and who developed acute
encephalitis (fever, aphasia, and a profound CSF mononuclear
pleocytosis). His CSF contained ampli®able VZV and Epstein±Barr
virus DNA. Zosteriform rash never developed, and he recovered
completely after treatment with intravenous acyclovir.
There have been two instances of polyneuritis cranialis produced
by VZV. The ®rst occurred in a 70-y-old man who seroconverted
to VZV during acute disease (Mayo and Booss, 1989). Another
report described a 43-y-old man with acute polyneuritis cranialis
who developed antibody in CSF to VZV, but not to other human
herpesviruses, or to multiple ubiquitous paramyxoviruses or
togaviruses (Osaki et al, 1995). Both men were apparently
immunocompetent. Finally, cases of acute unilateral facial (Bell's)
palsy that developed in the absence of zosteriform rash have been
attributed to VZV infection (so-called geniculate zoster sine
herpete) based on ``a positive serum complement ®xation test''
(Aitken and Brain, 1933). A recent study revealed that VZV was
the likely causative agent of acute peripheral facial palsy in 29% of
patients clinically diagnosed with Bell's palsy due to a lack of
vesicles in the external ear or on the palate (Furuta et al, 2000).
DIAGNOSIS
To con®rm the role of VZV in producing the many varied clinical
syndromes of the central and peripheral nervous system, polymerase
chain reaction and antibody testing of CSF should be performed, as
effective antiviral therapy exists. In the appropriate clinical setting
(i.e., acute or chronic spinal cord disease, acute or chronic
progressive encephalitis, or chronic radicular pain without rash),
the presence of VZV DNA or anti-VZV antibody, or both, in CSF
is strong presumptive evidence of VZV infection. Even the
detection of anti-VZV antibody in CSF without polymerase chain
reaction-ampli®able VZV DNA supports the diagnosis of VZV
infection of the nervous system (Gilden et al, 1998). Analysis of
serum anti-VZV antibody is of no value in the work-up of these
patients, because anti-VZV antibodies persist in nearly all adults
throughout life, and the presence of antibodies in serum to different
VZV glycoproteins and nonglycosylated proteins is variable (Vafai
et al, 1988a).
TREATMENT
The treatment for acute zoster generally includes analgesics such as
extra-strength acetaminophen and/or codeine 30±60 mg every 6 h
when necessary (Portenoy et al, 1986; Watson, 1993; Bowsher,
1994; Kost and Straus, 1996; Gilden et al, 2000). Oral acyclovir
(800 mg ®ve times daily) or famciclovir (500 mg three times daily)
has been reported to decrease new lesion formation and reduce
acute pain (Tyring et al, 1993; Wood et al, 1994). Although the
value of antiviral therapy, especially in immunocompetent indi-
viduals under age 50, remains to be de®nitively proven, our
practice is to prescribe oral acyclovir or famciclovir for 7 d if any
new skin lesions have developed within the past week. In addition,
all patients with ophthalmic distribution zoster should receive
antivirals for at least 7 d.
For the treatment of PHN, more than 40 pharmacologic,
antiseptic, and surgical therapies, including aspirin, hormones,
narcotics, vitamins, immunoglobulins, radiotherapy, and various
nerve blocks or excision, have been tried with limited success
(Watson, 1993). Tricyclic antidepressants, such as amitriptyline or
nortriptyline (25±75 mg at night), and the anticonvulsants
carbamazepine (400±1200 mg daily) and phenytoin (300±400 mg
daily), relieve pain in some PHN patients (Kost and Straus, 1996).
A recent report describes dramatic improvement of PHN with
gabapentin (neurontin), 300 mg three times daily (Segal and
Rordorf, 1996), and a randomized, placebo-controlled trial dem-
onstrated the effectiveness of gabapentin in PHN (Rowbotham et
al, 1998). A short course of steroids, e.g., prednisone (40±60 mg
daily for 3±5 d and sometimes longer), may reduce in¯ammation
contributing to pain. Subcutaneous infusion of ketamine reduced
PHN (Eide et al, 1995), but was associated with intolerable side-
effects. Topical aspirin in chloroform has been shown to relieve
zoster pain and PHN (King, 1993). Recently, the Food and Drug
Administration approved a topical lidocaine patch for the treatment
of PHN (Galer et al, 1999).
The more serious CNS and PNS complications of VZV
reactivation, including myelitis, encephalitis/arteritis, and radicu-
litis, are treated with intravenous acyclovir as soon as the diagnosis
is suspected. Treatment may then be withdrawn if negative results
are obtained for both anti-VZV antibody and VZV DNA from the
CSF. Otherwise, treatment should be continued for 10±14 d. The
rationale for such treatment is that VZV virions, antigen, and DNA
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are present in arteries of patients with large and small vessel
encephalitis (Fukumoto et al, 1986; Gilden et al, 1996).
SUMMARY
VZV reactivation is typically manifested as a zosteriform rash, and
may be associated with prolonged pain after resolution of rash
(PHN); however, several other CNS and PNS complications may
occur after VZV reactivation, many of which may not be
accompanied by rash. Therefore, neurologists, dermatologists, and
other specialists should be aware of these possible complications,
especially when caring for elderly and/or immunocompromised
patients.
REFERENCES
Aitken RS, Brain RT: Facial palsy and infection with zoster virus. Lancet 1:19±22,
1933
Amlie-Lefond C, Kleinschmidt-DeMasters BK, Mahalingam R, Davis LE, Gilden
DH: The vasculopathy of varicella zoster virus encephalitis. Ann Neurol
37:784±790, 1995
Amlie-Lefond C, Mackin GA, Ferguson M, Wright RR, Mahalingam R, Gilden
DH: Another case of virologically con®rmed zoster sine herpete, with
electrophysiologic correlation. J Neurovirol 2:136±138, 1996
Asano Y, Itakura N, Hiroishi Y, et al: Viremia is present in incubation period in
nonimmunocompromised children with varicella. J Pediatr 106:69±71, 1985
Baba K, Yabuuchi H, Takahaski M: Increased incidence of herpes zoster in normal
children infected with varicella zoster virus during infancy: Community-based
follow-up study. J Pediatr 108:372±377, 1986
Bowsher D: Post-herpetic neuralgia in older patients: incidence and optimal
treatment. Drugs Aging 5:411±418, 1994
Brown GR: Herpes zoster: correlation of age, sex, distribution, neuralgia and
associated disorders. South Med J 69:576±578, 1976
Brunell PA, Taylor-Wiedeman J, Geiser CF, Frierson L, Lydick E: Risk of herpes
zoster in children with leukemia. Varicella vaccine compared with history of
chickenpox. Pediatrics 77:53±56, 1986
Carroll WM, Mastaglia FL: Optic neuropathy and ophthalmoplegia in herpes zoster
oticus. Neurology 29:726±729, 1979
Crabtree JA: Herpes zoster oticus. Laryngoscope 78:1853±1879, 1968
DeMoragas JM, Kierland RR: The outcome of patients with herpes zoster. Arch
Dermatol 75:193±196., 1957
Dueland AN, Devlin M, Martin JR, et al: Fatal varicella zoster virus
meningoradiculitis without skin involvement. Ann Neurol 29:569±572, 1991
Easton HG: Zoster sine herpete causing acute trigeminal neuralgia. Lancet 2:1065±
1066, 1970
Echevarria JM, Martinez-Martin P, Tellez A, et al: Aseptic meningitis due to
varicella-zoster virus: Antibody levels and local synthesis of speci®c IgG, IgM
and IgA. J Infect Dis 155:959±967, 1987
Eide K, Stubhaug A, Oye I, Breivik H: Continuous subcutaneous administration of
the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the
treatment of post-herpetic neuralgia. Pain 61:221±228, 1995
Fenner F: The pathogenesis of the acute exanthems: An interpretation based on
experimental investigations with mousepox (infectious ectromelia of mice).
Lancet ii:915±920, 1948
Fukumoto S, Kinjo M, Hokamura K, Tanaka K: Subarachnoid hemorrhage and
granulomatous angiitis of the basilar artery: demonstration of the varicella-
zoster virus in the basilar artery lesions. Stroke 17:1024±1028, 1986
Furuta Y, Ohtani F, Kawabata H, Fukuda S, Bergstrom T: High prevalence of
varicella-zoster virus reactivation in herpes simplex virus-seronegative patients
with acute peripheral facial palsy. Clin Infect Dis 30:529±533, 2000
Galer BS, Rowbotham MC, Perander J, Friedman E: Topical lidocaine patch relieves
postherpetic neuralgia more effectively than a vehicle topical patch: results of an
enriched enrollment study. Pain 80:533±538, 1999
Garnett GP, Grenfell BT: The epidemiology of varicella-zoster virus infections: The
in¯uence of varicella on the prevalence of herpes zoster. Epidemiol Infect
108:513±528, 1992
Garty BZ, Dinari G, Sarnat H, Cohen S, Nitzan M: Tooth exfoliation and
osteonecrosis of the maxilla after trigeminal herpes zoster. J Pediatr 106:71±73,
1985
Gilden DH, Dueland AN, Cohrs R, Martin JR, Kleinschmidt-DeMasters BK,
Mahalingam R: Preherpetic neuralgia. Neurology 41:1215±1218, 1991
Gilden DH, Beinlich BR, Rubinstien EM, Stommel E, Swenson R, Rubinstein D,
Mahalingam R: VZV myelitis: An expanding spectrum. Neurology 44:1818±
1823, 1994a
Gilden DH, Wright RR, Schneck SA, Gwaltney JM Jr, Mahalingam R: Zoster sine
herpete, a clinical variant. Ann Neurol 35:530±533, 1994b
Gilden DH, Kleinschmidt-DeMasters BK, Wellish M, Hedley-Whyte ET, Rentier
B, Mahalingam R: Varicella zoster virus, a cause of waxing and waning
vasculitis. NEJM case 5±1995 revisited. Neurology 47:1441±1446, 1996
Gilden DH, Bennett JL, Kleinschmidt-DeMasters BK, Song DD, Yee AS, Steiner I:
The value of cerebrospinal ¯uid antiviral antibody in the diagnosis of
neurologic disease produced by varicella zoster virus. J Neurol Sci 159:140±
144, 1998
Gilden DH, Kleinschmidt-DeMasters BK, LaGuardia JJ, Mahalingam R, Cohrs R:
Neurologic complications of the reactivation of varicella-zoster virus. N Engl J
Med 342:635±645, 2000
Grose C: Variation on a theme by Fenner. The pathogenesis of chickenpox. Pediatrics
68:735±737, 1981
Guess HA, Broughton DD, Melton LJ, Kurland LT: Epidemiology of herpes zoster
in children and adolescents. A population-based study. Pediatrics 76:512±517,
1985
Gustafson TL, Lavely GB, Brawner ER Jr, Hutcheson RH Jr, Wright PF, Schaffner
W: An outbreak of airborne nosocomial varicella. Pediatrics 70:550±556, 1982
Halloran ME: Epidemiologic effects of varicella vacinnation. Infect Dis Clin North Am
10:631±655, 1996
Hardy I, Gershon AA, Steinberg SP, LaRussa P, and the Varicella Vaccine Collaborative
Study Group: The incidence of zoster after immunization with live attenuated
varicella vaccine. N Engl J Med 325:1545±1550, 1991
Harnisch JP: Zoster in the elderly: Clinical, immunologic and therapeutic
considerations. J Am Geriatr Soc 32:789±793, 1984
Heller HM, Carnevale NT, Steigbigel RT: Varicella zoster virus transverse myelitis
without cutaneous rash. Am J Med 88:550±551, 1990
Hope-Simpson RE: The nature of herpes zoster: a long-term study and a new
hypothesis. Proc R Soc Med 58:9±20, 1965
Hope-Simpson RE: Postherpetic neuralgia. J Royal College Gen Pract 25:571±575,
1975
Josephson A, Gombert ME: Airborne transmission of nosocomial varicella from
localized zoster. J Infect Dis 158:238±241, 1988
Kallander CF, Gronowitz JS, Olding-Stenkvist E: Varicella zoster virus
deoxythymidine kinase is present in serum before the onset of varicella.
Scand J Infect Dis 21:255±257, 1989
King RB: Topical aspirin in chloroform and the relief of pain due to herpes zoster
and postherpetic neuralgia. Arch Neurol 50:1046±1053, 1993
Kleinschmidt-DeMasters BK, Amlie-Lefond D, Gilden DH: The patterns of varicella
zoster virus encephalitis. Hum Pathol 27:927±938, 1996
Kleinschmidt-DeMasters BK, Mahalingam R, Shimek C, Marcoux HL, Wellish M,
Tyler KL, Gilden DH: Profound cerebrospinal ¯uid pleocytosis and Froin's
syndrome secondary to widespread necrotizing vasculitis in an HIV-positive
patient with varicella zoster virus encephalomyelitis. J Neurol Sci 159:213±218,
1998
Koropchak CM, Solem SD, Diaz PS, Arvin AM: Investigation of varicella-zoster
virus infection of lymphocytes by in situ hybridization. J Virol 63:2392±2395,
1989
Kost RG, Straus SE: Postherpetic neuralgia B pathogenesis, treatment, and
prevention. N Engl J Med 335:32±42, 1996
Leclair JM, Zaia JA, Levin MJ, Congdon RG, Goldmann DA: Airborne transmission
of chickenpox in a hospital. N Engl J Med 302:450±453, 1980
Lewis GW: Zoster sine herpete. Br Med J 2:418±421, 1958
Long®eld JN, Winn RE, Gibson RL, Juchau SV, Hoffman PV: Varicella outbreaks
in army recruits from Puerto Rico. Arch Intern Med 150:970±973, 1990
Mahalingam R, Wellish M, Lederer D, Forghani B, Cohrs R, Gilden D:
Quantitation of latent varicella-zoster virus DNA in human trigeminal
ganglia by polymerase chain reaction. J Virol 67:2381±2384, 1993
Mahalingam R, Wellish M, Brucklier J, Gilden DH: Persistence of varicella-zoster
virus DNA in elderly patients with postherpetic neuralgia. J Neurovirol 1:130±
133, 1995
Manz HJ, Canter HG, Melton J: Trigeminal herpes zoster causing mandibular
osteonecrosis and spontaneous tooth exfoliation. South Med J 79:1026±1028,
1986
Martinez-Martin P, Garcia-Saiz A, Rapun JL, Echevarria JM: Intrathecal synthesis of
IgG antibodies to varicella-zoster virus in two cases of acute aseptic meningitis
syndrome with no cutaneous lesions. J Med Virol 16:201±209, 1985
Mayo DR, Booss J: Varicella zoster-associated neurologic disease without skin
lesions. Arch Neurol 46:313±315, 1989
Miller DH, Kay R, Schon F, McDonald WI, Haas LF, Hughes RA: Optic neuritis
following chickenpox in adults. J Neurol 233:182±184, 1986
Nassar NT, Touma HC: Susceptibility of Filipino nurses to the varicella-zoster virus.
Infect Control 7:71±72, 1986
Ozaki T, Ichikawa T, Matsui Y, et al: Lymphocyte-associated viremia in varicella. J
Med Virol 19:249±253, 1986
Osaki Y, Matsubayashi K, Okumiya K, Wada T, Doi Y: Polyneuritis cranialis due to
varicella-zoster virus in the absence of rash. Neurology 45:2293, 1995
Portenoy RK, Duma C, Foley KM: Acute herpetic and postherpetic neuralgia:
clinical review and current management. Ann Neurol 20:651±664, 1986
Preblud SR: Varicella complications and costs. Pediatrics 78:728±735, 1986
Preblud SR, D'Angelo LJ: From the Center for Disease Control. Chickenpox in the
United States. J Infect Dis 140:257±260, 1979
Preblud SR, Orenstein WA, Bart KJ: Varicella: Clinical manifestations, epidemiology
and health impact in children. Pediatr Infect Dis 3:505±509, 1984
Ragozzino MW, Melton LJ III, Kurland LT, Chu CP, Perry HO: Population-based
study of herpes zoster and its sequelae. Medicine (Baltimore) 61:310±316, 1982
Rogers RS, Tindall JP: Geriatric herpes zoster. J Am Geriatr Soc 19:495±503, 1971
Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L: Gabapentin for
the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA
280:1837±1842, 1998
Schott GD: Triggering of delayed-onset postherpetic neuralgia. Lancet 351:419±420,
1998
Segal AZ, Rordorf G: Gabapentin as a novel treatment for postherpetic neuralgia.
Neurology 46:1175±1176, 1996
Steffen R, Selby G: ``Atypical'' Ramsay Hunt syndrome. Med J Aust 1:227±230, 1972
186 LAGUARDIA AND GILDEN JID SYMPOSIUM PROCEEDINGS
Thomas EJ, Howard FM: Segmental zoster paresis ± a disease pro®le. Neurology
22:459±466, 1972
Tomlinson TH: Giant cell formation in the tonsils in the prodromal stage of
chickenpox. Am J Path 15:523±526, 1939
Tyring S, Nahlik J, Cunningham A, and the Collaborative Famciclovir Herpes Zoster
Study Group: Ef®cacy and safety of famciclovir in the treatment of patients with
herpes zoster: results of the ®rst placebo-controlled study. In: Program and
Abstractions of the 33rd Interscience Conference on Antimicrobial Agents and
Chemotherapy, October 17±20, 1993. New Orleans: American Society for
Microbiology, 1993, p. 400
Tyzzer EE: The histology of the skin lesions in varicella. Philippine J Sci 1:349±372,
1906
Vafai A, Mahalingam R, Zerbe G, Wellish M, Gilden DH: Detection of antibodies to
varicella-zoster virus proteins in sera from the elderly. Gerontology 34:242±249,
1988a
Vafai A, Murray RS, Wellish M, Devlin M, Gilden DH: Expression of varicella-
zoster virus and herpes simplex virus in normal human trigeminal ganglia. Proc
Natl Acad Sci USA 85:2362±2366, 1988b
Vartdal F, Vandvik B, Norby E: Intrathecal synthesis of virus-speci®c oligoclonal
IgG, IgA and IgM antibodies in a case of varicella-zoster meningoencephalitis. J
Neurol Sci 57:121±132, 1982
Vonsover A, Leventon-Kriss S, Langer A, et al: Detection of varicella-zoster virus in
lymphocytes by DNA hybridization. J Med Virol 21:57±66, 1987
Watson CPN: Pain Research and Clinical Management, Vol. 8, Herpes Zoster and
Postherpetic Neuralgia. Amsterdam: Elsevier, 1993
Weber FP: Herpes zoster: its occasional association with a generalized eruption and
its occasional connection with muscular paralysis; also an analysis of the
literature of the subject. Int Clin 3:185±202, 1916
Weller TH, Witton HM, Bell EJ: The etiologic agents of varicella and herpes zoster.
Isolation, propagation, and cultural characteristics in vitro. J Exp Med 108:843±
868, 1958
Wharton M: The epidemiology of varicella-zoster virus infections. Infect Dis Clin
North Am 10:571±581, 1996
Widal: J Med Chiropractic Pract 78:12, 1907
Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J: A
randomized trial of acyclovir for 7 days or 21 days with and without
prednisolone for treatment of acute herpes zoster. N Engl J Med 330:896±900,
1994
VOL. 6, NO. 3 DECEMBER 2001 VZV: NEUROLOGIC COMPLICATIONS 187
